-
公开(公告)号：US20090326202A1
公开(公告)日：2009-12-31
申请号：US12474176
申请日：2009-05-28
IPC分类号： C07K16/18
CPC分类号： C07K16/40 , A61K31/22 , A61K31/366 , A61K31/40 , A61K31/405 , A61K31/44 , A61K31/47 , A61K31/505 , A61K31/66 , A61K39/395 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2299/00 , C07K2317/14 , C07K2317/34 , C07K2317/76 , C07K2317/92 , C12N15/1137 , A61K2300/00
摘要： Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
-
公开(公告)号：US20080096900A1
公开(公告)日：2008-04-24
申请号：US11823251
申请日：2007-06-26
申请人： Frank Kayser , Marc LaBelle , Bei Shan , Jian Zhang , Mingyue Zhou
发明人： Frank Kayser , Marc LaBelle , Bei Shan , Jian Zhang , Mingyue Zhou
IPC分类号： A61K31/497 , A61P9/00
CPC分类号： C12N9/1029 , A61K31/497 , A61K38/45 , C07D403/12 , C07D417/12
摘要： The invention provides compounds, pharmaceutical compositions and methods for treating atherosclerosis, inflammation, thrombosis and other conditions and for decreasing or prevention of accumulation of cholesterol in a subject by modifying LCAT polypeptide.
摘要翻译： 本发明提供了通过改变LCAT多肽来治疗动脉粥样硬化，炎症，血栓形成和其它病症并降低或预防受试者胆固醇积聚的化合物，药物组合物和方法。
-
公开(公告)号：US06482860B1
公开(公告)日：2002-11-19
申请号：US08896280
申请日：1997-07-18
IPC分类号： A61K3118
CPC分类号： C07K14/47 , A61K31/18 , A61K31/255 , A61K31/357 , A61K31/36 , A61K31/404 , A61K31/415 , A61K31/416 , A61K31/44 , A61K31/47 , A61K31/5375 , C07C309/73 , C07C311/21 , C07C313/06 , C07C323/49 , C07D209/08 , C07D213/76 , C07D231/56 , C07D295/135 , C07D317/66 , C07D319/18 , Y02A50/411
摘要： The invention provides methods and compositions relating to novel pentafluorophenylsulfonamide derivatives and analogs and their use as pharmacologically active agents. The compositions find particular use as pharmacological agents in the treatment of disease states, particularly cancer, vascular restenosis, microbial infections, and psoriasis, or as lead compounds for the development of such agents. The compositions include compounds of the general formula I:
摘要翻译： 本发明提供了与新的五氟苯基磺酰胺衍生物和类似物有关的方法和组合物及其作为药理活性剂的用途。 该组合物特别用作治疗疾病状态，特别是癌症，血管再狭窄，微生物感染和牛皮癣的药理作用，或作为用于开发这种药物的铅化合物。 组合物包括通式I的化合物：
-
公开(公告)号：US06465258B1
公开(公告)日：2002-10-15
申请号：US09478948
申请日：2000-01-06
申请人： Bei Shan , Arthur Y Okamoto
发明人： Bei Shan , Arthur Y Okamoto
IPC分类号： G01N33566
CPC分类号： G01N33/92 , A61K31/00 , A61K31/575 , G01N33/6872 , G01N33/6875 , G01N2333/70567 , G01N2500/04 , G01N2800/044
摘要： This invention provides methods and compositions that are useful for modulating cholesterol levels in a cell, and for identifying compounds that can tested for ability to modulate cholesterol levels in mammals. In vitro assays for prescreening to identify candidate therapeutic agents for modulation of cholesterol metabolism are provided. These methods involve analyzing the effect of a test compound on the binding of FXR to a ligand for FXR. Such ligands include, for example, bile acids, coactivators, and corepressors. The methods and compositions involve modulating FXR-mediated expression of genes involved in cholesterol metabolism.
摘要翻译： 本发明提供了可用于调节细胞中胆固醇水平的方法和组合物，并且用于鉴定可测试哺乳动物胆固醇水平调节能力的化合物。 提供了用于预筛选以鉴定用于调节胆固醇代谢的候选治疗剂的体外测定。 这些方法包括分析试验化合物对FXR与FXR配体结合的影响。 这样的配体包括例如胆汁酸，共激活剂和共抑制因子。 所述方法和组合物涉及调节涉及胆固醇代谢的基因的FXR介导的表达。
-
公开(公告)号：US06316484B1
公开(公告)日：2001-11-13
申请号：US09633740
申请日：2000-08-07
IPC分类号： C07D40900
CPC分类号： C07D319/18 , A61K31/18 , A61K31/275 , A61K31/357 , A61K31/404 , A61K31/416 , A61K31/44 , A61K31/5375 , C07C311/21 , C07C311/29 , C07C323/49 , C07D209/08 , C07D213/75 , C07D231/56 , C07D317/66
摘要： The invention provides methods and compositions relating to novel pentafluorophenylsulfonamide derivatives and analogs and their use as pharmacologically active agents. The compositions find particular use as pharmacological agents in the treatment of disease states, particularly atherosclerosis and hypercholesterolemia, or as lead compounds for the development of such agents. The compositions include compounds of the general formula I:
摘要翻译： 本发明提供了与新的五氟苯基磺酰胺衍生物和类似物有关的方法和组合物及其作为药理活性剂的用途。 该组合物特别用作治疗疾病状态，特别是动脉粥样硬化和高胆固醇血症中的药理学作用，或作为用于开发此类药物的铅化合物。 组合物包括通式I的化合物：
-
26.发明授权公开(公告)号：US10752664B2
公开(公告)日：2020-08-25
申请号：US14009790
申请日：2012-04-05
申请人： YuMei Xiong , Yang Li , Wen-Chen Yeh , Bei Shan , Jackie Zeqi Sheng
发明人： YuMei Xiong , Yang Li , Wen-Chen Yeh , Bei Shan , Jackie Zeqi Sheng
IPC分类号： C07K14/495 , A61K38/00 , A61K38/18
摘要： Methods of treating metabolic diseases and disorders using a GDF15 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
-
27.发明授权Methods of using antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) 有权使用抗原结合蛋白将蛋白转化酶枯草杆菌蛋白酶Kexin 9型（PCSK9）公开(公告)号：US09045547B2
公开(公告)日：2015-06-02
申请号：US13251909
申请日：2011-10-03
申请人： Simon Mark Jackson , Nigel Pelham Clinton Walker , Derek Evan Piper , Bei Shan , Wenyan Shen , Joyce Chi Yee Chan , Chadwick Terence King , Randal Robert Ketchem , Christopher Mehlin , Teresa Arazas Carabeo
发明人： Simon Mark Jackson , Nigel Pelham Clinton Walker , Derek Evan Piper , Bei Shan , Wenyan Shen , Joyce Chi Yee Chan , Chadwick Terence King , Randal Robert Ketchem , Christopher Mehlin , Teresa Arazas Carabeo
IPC分类号： A61K39/395 , C07K16/40 , A61K31/22 , A61K31/366 , A61K31/40 , A61K31/405 , A61K31/44 , A61K31/47 , A61K31/505 , A61K31/66 , A61K45/06 , C12N15/113 , A61K39/00
CPC分类号： C07K16/40 , A61K31/22 , A61K31/366 , A61K31/40 , A61K31/405 , A61K31/44 , A61K31/47 , A61K31/505 , A61K31/66 , A61K39/395 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2299/00 , C07K2317/14 , C07K2317/34 , C07K2317/76 , C07K2317/92 , C12N15/1137 , A61K2300/00
摘要： Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
摘要翻译： 描述了与Proprotein转化酶枯草杆菌蛋白酶Kexin 9型（PCSK9）相互作用的抗原结合蛋白。 描述了通过向PCSK9施用药学有效量的抗原结合蛋白来治疗高胆固醇血症和其它病症的方法。 描述了使用抗原结合蛋白质向PCSK9检测样品中PCSK9的量的方法。
-
公开(公告)号：US20130072665A1
公开(公告)日：2013-03-21
申请号：US13619555
申请日：2012-09-14
申请人： Simon Mark Jackson , Nigel Pelham Clinton Walker , Derek Evan Piper , Bei Shan , Wenyan Shen , Joyce Chi Yee Chan , Chadwick Terrence King , Randal Robert Ketchem , Christopher Mehlin , Teresa Arazas Carabeo , Qiong Cao
发明人： Simon Mark Jackson , Nigel Pelham Clinton Walker , Derek Evan Piper , Bei Shan , Wenyan Shen , Joyce Chi Yee Chan , Chadwick Terrence King , Randal Robert Ketchem , Christopher Mehlin , Teresa Arazas Carabeo , Qiong Cao
IPC分类号： C07K16/40
CPC分类号： C07K16/40 , A61K31/22 , A61K31/366 , A61K31/40 , A61K31/405 , A61K31/44 , A61K31/47 , A61K31/505 , A61K31/66 , A61K39/395 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2299/00 , C07K2317/34 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
-
公开(公告)号：US20120213797A1
公开(公告)日：2012-08-23
申请号：US13463751
申请日：2012-05-03
申请人： Simon Mark Jackson , Nigel Pelham Clinton Walker , Derek Evan Piper , Bei Shan , Wenyan Shen , Joyce Chi Yee Chan , Chadwick Terence King , Randal Robert Ketchem , Christopher Mehlin , Teresa Arazas Carabeo , Qiong Cao
发明人： Simon Mark Jackson , Nigel Pelham Clinton Walker , Derek Evan Piper , Bei Shan , Wenyan Shen , Joyce Chi Yee Chan , Chadwick Terence King , Randal Robert Ketchem , Christopher Mehlin , Teresa Arazas Carabeo , Qiong Cao
IPC分类号： C07K16/40 , A61K39/395
摘要： Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
-
公开(公告)号：US20120027765A1
公开(公告)日：2012-02-02
申请号：US13252016
申请日：2011-10-03
申请人： Simon Mark Jackson , Nigel Pelham Clinton Walker , Derek Evan Piper , Bei Shan , Wenyan Shen , Joyce Chi Yee Chan , Chadwick Terence King , Randal Robert Ketchem , Christopher Mehlin , Teresa Arazas Carabeo , Qiong Cao
发明人： Simon Mark Jackson , Nigel Pelham Clinton Walker , Derek Evan Piper , Bei Shan , Wenyan Shen , Joyce Chi Yee Chan , Chadwick Terence King , Randal Robert Ketchem , Christopher Mehlin , Teresa Arazas Carabeo , Qiong Cao
IPC分类号： A61K39/395 , A61P3/00 , C07K16/40
CPC分类号： C07K16/40 , A61K31/22 , A61K31/366 , A61K31/40 , A61K31/405 , A61K31/44 , A61K31/47 , A61K31/505 , A61K31/66 , A61K39/395 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2299/00 , C07K2317/14 , C07K2317/34 , C07K2317/76 , C07K2317/92 , C12N15/1137 , A61K2300/00
摘要： Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
-
-
-
-
-
-
-
-
-
搜索结果
47 条记录 (耗时 0.055 秒)
